Human NKp46/NCR1 Alexa Fluor® 350-conjugated Antibody

Applications

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Preparation and Storage

Background: NKp46/NCR1

NKp46, along with NKp30 and NKp44, are activating receptors that have been collectively termed the natural cytotoxicity receptors (NCR) (1). These receptors lack significant sequence homology to one another. They are expressed almost exclusively by NK cells and play a major role in triggering some of the key lytic activities of NK cells. The CD56^dimCD16⁺ subpopulation that makes up the majority of NK cells in the peripheral blood and spleen expresses NKp46 in both resting and activated states (2). The main NK cell population of the lymph node (CD56^brightCD16^-) expresses low levels of NKp46 in resting cells, but expression is up-regulated by IL-2. NKp46 is a type I transmembrane protein with two extracellular Ig-like domains followed by a short stalk region, a transmembrane domain containing a positively charged amino acid residue, and a short cytoplasmic tail. Through its positive charge in the transmembrane domain, NKp46 associates with the ITAM‑bearing signal adapter proteins, CD3 zeta and Fc epsilon R1 gamma, which are able to form disulfide-linked homodimers and heterodimers (3, 8). Studies with neutralizing antibodies indicate that the three NCRs are primarily responsible for triggering the NK-mediated lysis of many human tumor cell lines. Blocking any of the NCRs individually resulted in partial inhibition of tumor cell lysis, but nearly complete inhibition of lysis was observed if all three receptors were blocked simultaneously (4). NKp46 has also been implicated in recognition of virus-infected cells through its capacity to bind to viral hemagglutinins (5‑7). Human NKp46 shares 58% and 59% amino acid sequence identity with the mouse and rat proteins, respectively.

Product Datasheets

Product Specific Notices

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

Related Research Areas

• Group 1 ILCs
• Isolation, Culture, and Identification of Natural Killer Cells
• ITIM/ITAM Immunoreceptors and Related Molecules
• Lymphoid Lineage Markers
• Natural Cytotoxicity Receptors (NCRs) and Ligands
• Natural Killer T (NKT) Cells
• NCR+ILC3
• NCR-ILC3